Use of patient age and anti-Ro/La antibody status to determine the probability of patients with systemic lupus erythematosus and sicca symptoms fulfilling criteria for secondary Sjogren's syndrome

Identification of autoantibody biomarkers for primary Sjögren's syndrome using protein microarrays

“…These signature autoantibodies, once identified and validated, will allow a clinical tool for the diagnosis of sSS in patients with SLE or RA and also for differentiation of two forms of SS. In fact, the previous studies have shown an association between the presence of anti‐SSA/anti‐SSB and the development of sSS in patients with SLE, which provided evidence of using autoantibodies to classify the patients with sSS 28. In addition, the microarray approach can also be used to reveal autoantibody biomarkers for SS‐associated MALT lymphoma, which is a cancer of B‐cell lymphocytes (extranodal marginal zone B‐cell lymphoma).…”

Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sjögren’s syndrome (secondary Sjögren’s syndrome) focusing on autoimmune rheumatic diseases

“…We found 18 studies which looked at the prevalence of RA-sSS (between 1987-2013) (16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33), 13 for SLE-sSS (1998-2015) (34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46), 6 for SSc-sSS (1983-2013) (47-52) and 3 for myositis-sSS (2011-2014) (53)(54)(55). The prevalence ranged from 3.6%-55% for RA-sSS, 5%-22% SLE-sSS, 14%-60% SSc-sSS and 10-23% for myositis-sSS.…”

Oral yeast colonization in patients with primary and secondary Sjögren's syndrome

“…It is the second most common rheumatic autoimmune disease with an estimated prevalence ranging between 0.1 and 4.8%, considering different studies worldwide (Mavragani & Moutsopoulos, 2010;Tincani et al, 2013;Vitali et al, 2013). While there are several diagnostic criteria for diagnosis of SS, international diagnostic criteria were developed to standardize the classification of SS patients included in clinical and/or therapeutic trials (Prabu et al, 2003;Vitali et al, 2002).…”